vorasidenib
servier
['vorasidenib', 'ag-881', 'servier']
servier s fast-track designated vorasidenib/ag-881 (midh1 and midh2 dual inhibitor) demonstrated unprecedented mpfs in residual or recurrent grade 2 glioma with an idh1 or idh2 mutation. the results were presented at asco 2023 plenary session by ingo k. mellinghoff, memorial 
Oncofocus will tweet about matters related to Oncology. Views expressed are our own.